Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy elderly subjects ≥65 years,~2. Individuals willing to provide written informed consent,~3. Individuals in good health,~4. Individuals willing to allow for their serum samples to be stored beyond the study period.~Exclusion Criteria:~1. Individuals not able to understand and follow study procedures,~2. History of any significant illness,~3. History of any serious chronic medical condition or progressive disease,~4. Presence of medically significant cancer,~5. Known or suspected impairment/alteration of immune function,~6. Presence of any progressive or severe neurologic disorder,~7. Presence of any bleeding disorders or conditions that prolongs bleeding time,~8. History of allergy to vaccine components,~9. Receipt of any other investigational product within 30 days prior to entry into the study,~10. History of previous H5N1 vaccination,~11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,~12. Receipt of any other vaccine within 2 weeks prior to entry into the study~13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,~14. Body mass index (BMI) ≥ 35 kg/m2,~15. History of drug or alcohol abuse,~16. Any planned surgery during study period,~17. Individuals conducting the study and their immediate family members,~18. Individuals with behavioral or cognitive impairment or psychiatric diseases.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- aH5N1c - High dose (Type: EXPERIMENTAL): None
- aH5N1c - Low dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).